Structural and functional role of HIV-1 gp41 terminal interactions in the membrane fusion mechanism

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/543125

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Approximately 40 million individuals are currently living with HIV. The viral glycoproteins, gp120-gp41, mediate the first stage of infection, membrane fusion, and thus serve as targets for vaccines and antiviral agents. Thi proposal seeks to assess the structure and function of a potential new drug target in gp120-gp41. These studies may lead to the identification of a new antiviral that blocks membrane fusion. Such agents can be added to antiviral drug cocktails for more effective therapy.

Funded Activity Details

Start Date: 01-01-2009

End Date: 01-01-2011

Funding Scheme: NHMRC Project Grants

Funding Amount: $529,632.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Applied immunology (incl. antibody engineering xenotransplantation and t-cell therapies)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

HIV infection | HIV-AIDS | Infectious disease | antiviral drug | membrane fusion | molecular biology | protein chemistry | viral glycoproteins

Related Links